Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for B-Cell Malignancy and Autoimmune Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FCRL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FCRL1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View FCRL1 Products |
| Gene Delivery | FCRL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View FCRL1 Products |
| Benchmark Ab | Anti-FCRL1 (Sequence of Clinical Benchmarks) Recombinant positive control. |
View FCRL1 Products |
| Validator | FCRL1 siRNA Set For knockdown verification. |
View FCRL1 Products |
| Related Target A | FCRL5 Homolog counter-screening to ensure specificity and avoid off-target binding in the FCRL family. |
View FCRL5 Products |
| Related Target B | CD3E Crucial co-target for T-cell engaging bispecific antibody (BsAb) development. |
View CD3E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| FCRL family cross-reactivity and off-target screening | Human/Mouse/Cyno ortholog proteins available with >95% purity verified by SDS-PAGE |
| Subfamily counter-screening (FCRL2-5) | Homolog panel proteins strictly verified by mass spectrometry and sequence-matched |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live FCRL1/CD307a R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FCRL1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific T-cell engagers (TCEs) and CAR-T cell therapies. As first-generation B-cell therapies (targeting CD19, CD20, or BCMA) face antigen escape and resistance, the next wave of R&D is targeting FCRL1 due to its highly restricted expression on B-lineage cells, making it an ideal candidate for treating B-cell malignancies and autoimmune diseases.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Bispecific Antibodies (FCRL1 x CD3) | Biotech Innovators, Academic Labs | Non-Hodgkin Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL) | Heterodimer Validation (Need high-purity FCRL1 and CD3E proteins) |
| CAR-T / Cell Therapies | Cell Therapy Developers | B-cell Malignancies, Refractory Autoimmune Diseases | Target Expression & Transduction Verification (Need Lentivirus for Stable Cell Lines) |
| Antibody-Drug Conjugates (ADCs) | Oncology-focused Biopharma | B-cell Lymphomas | Internalization Assay (Need HEK293-expressed, natively glycosylated FCRL1 ECD-Fc) |